Literature DB >> 16302333

Fibrolamellar hepatocellular carcinoma in a 65-year-old woman: CT features.

J Marrannes1, S Gryspeerdt, M Haspeslagh, B van Holsbeeck, M Baekelandt, Ph Lefere.   

Abstract

A 65-year old woman with recurrent deep vein thrombosis underwent a CT scan of the upper abdomen for detection of underlying malignancy. A fibrolamellar hepatocellular carcinoma with extrahepatic subdiaphragmatic satellite lesion was found. This uncommon tumor has distinct clinical, pathological, radiological and prognostic features and therefore it is important to distinguish it from benign liver tumors, especially FNH, and from other malignant liver tumors such as conventional HCC. Though the tumor characteristically occurs in younger patients, our case proves that older patients can also be affected.

Entities:  

Mesh:

Year:  2005        PMID: 16302333

Source DB:  PubMed          Journal:  JBR-BTR        ISSN: 0302-7430


  5 in total

1.  Fibrolamellar hepatocellular carcinoma presenting as obstructive jaundice: uncommon presentation of a rare entity.

Authors:  Richa Arora
Journal:  Pol J Radiol       Date:  2015-03-31

Review 2.  Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.

Authors:  Walaa Abdelhamed; Mohamed El-Kassas
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

3.  Case 1-2011: a 26 year-old man with right lower limb edema and liver mass.

Authors:  R Taslimi; R Malekzadeh; M Rahmani; F Azmodeh Ardalan
Journal:  Middle East J Dig Dis       Date:  2011-03

Review 4.  Fibrolamellar hepatocellular carcinoma: current clinical perspectives.

Authors:  Kelly J Lafaro; Timothy M Pawlik
Journal:  J Hepatocell Carcinoma       Date:  2015-10-09

5.  Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.

Authors:  Anastasia Lemekhova; Daniel Hornuss; Georgios Polychronidis; Philipp Mayer; Christian Rupp; Thomas Longerich; Karl-Heinz Weiss; Markus Büchler; Arianeb Mehrabi; Katrin Hoffmann
Journal:  World J Surg Oncol       Date:  2020-05-12       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.